                         SEQUENCE LISTING

<110>  Transgene SA
 
<120>  Fusion of heterooligomeric mycobacterial antigens

<130>  B366981 D34574

<150>  EP 14305030.0
<151>  2014-01-09

<160>  33    

<170>  PatentIn version 3.5

<210>  1
<211>  208
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion between CFP10 and its partner ESAT-6

<400>  1

Met Ala Glu Met Lys Thr Asp Ala Ala Thr Leu Ala Gln Glu Ala Gly 
1               5                   10                  15      


Asn Phe Glu Arg Ile Ser Gly Asp Leu Lys Thr Gln Ile Asp Gln Val 
            20                  25                  30          


Glu Ser Thr Ala Gly Ser Leu Gln Gly Gln Trp Arg Gly Ala Ala Gly 
        35                  40                  45              


Thr Ala Ala Gln Ala Ala Val Val Arg Phe Gln Glu Ala Ala Asn Lys 
    50                  55                  60                  


Gln Lys Gln Glu Leu Asp Glu Ile Ser Thr Asn Ile Arg Gln Ala Gly 
65                  70                  75                  80  


Val Gln Tyr Ser Arg Ala Asp Glu Glu Gln Gln Gln Ala Leu Ser Ser 
                85                  90                  95      


Gln Met Gly Phe Gly Pro Lys Gln Gly Glu Asp Asp Gly Ser Thr Gly 
            100                 105                 110         


Gly Pro Thr Glu Gln Gln Trp Asn Phe Ala Gly Ile Glu Ala Ala Ala 
        115                 120                 125             


Ser Ala Ile Gln Gly Asn Val Thr Ser Ile His Ser Leu Leu Asp Glu 
    130                 135                 140                 


Gly Lys Gln Ser Leu Thr Lys Leu Ala Ala Ala Trp Gly Gly Ser Gly 
145                 150                 155                 160 


Ser Glu Ala Tyr Gln Gly Val Gln Gln Lys Trp Asp Ala Thr Ala Thr 
                165                 170                 175     


Glu Leu Asn Asn Ala Leu Gln Asn Leu Ala Arg Thr Ile Ser Glu Ala 
            180                 185                 190         


Gly Gln Ala Met Ala Ser Thr Glu Gly Asn Val Thr Gly Met Phe Ala 
        195                 200                 205             


<210>  2
<211>  205
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion between TB10.4 and its parner TB9.8 (Rv0287)

<400>  2

Met Ser Gln Ile Met Tyr Asn Tyr Pro Ala Met Leu Gly His Ala Gly 
1               5                   10                  15      


Asp Met Ala Gly Tyr Ala Gly Thr Leu Gln Ser Leu Gly Ala Glu Ile 
            20                  25                  30          


Ala Val Glu Gln Ala Ala Leu Gln Ser Ala Trp Gln Gly Asp Thr Gly 
        35                  40                  45              


Ile Thr Tyr Gln Ala Trp Gln Ala Gln Trp Asn Gln Ala Met Glu Asp 
    50                  55                  60                  


Leu Val Arg Ala Tyr His Ala Met Ser Ser Thr His Glu Ala Asn Thr 
65                  70                  75                  80  


Met Ala Met Met Ala Arg Asp Thr Ala Glu Ala Ala Lys Trp Gly Gly 
                85                  90                  95      


Gly Pro Lys Gln Gly Glu Asp Asp Gly Ser Thr Gly Gly Ser Leu Leu 
            100                 105                 110         


Asp Ala His Ile Pro Gln Leu Val Ala Ser Gln Ser Ala Phe Ala Ala 
        115                 120                 125             


Lys Ala Gly Leu Met Arg His Thr Ile Gly Gln Ala Glu Gln Ala Ala 
    130                 135                 140                 


Met Ser Ala Gln Ala Phe His Gln Gly Glu Ser Ser Ala Ala Phe Gln 
145                 150                 155                 160 


Ala Ala His Ala Arg Phe Val Ala Ala Ala Ala Lys Val Asn Thr Leu 
                165                 170                 175     


Leu Asp Val Ala Gln Ala Asn Leu Gly Glu Ala Ala Gly Thr Tyr Val 
            180                 185                 190         


Ala Ala Asp Ala Ala Ala Ala Ser Thr Tyr Thr Gly Phe 
        195                 200                 205 


<210>  3
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  mutant of Rv1813 antigen

<400>  3

Asp Ala His Leu Ala Asn Gly Ser Met Ser Glu Val Met Met Ser Glu 
1               5                   10                  15      


Ile Ala Gly Leu Pro Ile Pro Pro Ile Ile His Tyr Gly Ala Ile Ala 
            20                  25                  30          


Tyr Ala Pro Ser Gly Ala Ser Gly Lys Ala Trp His Gln Arg Thr Pro 
        35                  40                  45              


Ala Arg Ala Glu Gln Val Ala Leu Glu Lys Cys Gly Asp Lys Thr Cys 
    50                  55                  60                  


Lys Val Val Ser Arg Phe Thr Arg Cys Gly Ala Val Ala Tyr Asn Gly 
65                  70                  75                  80  


Ser Lys Tyr Gln Gly Gly Thr Gly Leu Thr Arg Arg Ala Ala Glu Asp 
                85                  90                  95      


Asp Ala Val Asn Arg Leu Glu Gly Gly Arg Ile Val Asn Trp Ala Cys 
            100                 105                 110         


Asn 
    


<210>  4
<211>  293
<212>  PRT
<213>  artificial sequence

<220>
<223>  mutant of Ag85B antigen

<400>  4

Gly Gly Ala Ala Thr Ala Gly Ala Phe Ser Arg Pro Gly Leu Pro Val 
1               5                   10                  15      


Glu Tyr Leu Gln Val Pro Ser Pro Ser Met Gly Arg Asp Ile Lys Val 
            20                  25                  30          


Gln Phe Gln Ser Gly Gly Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp 
        35                  40                  45              


Gly Leu Arg Ala Gln Asp Asp Tyr Asn Gly Trp Asp Ile Asn Thr Pro 
    50                  55                  60                  


Ala Phe Glu Trp Tyr Tyr Gln Ser Gly Leu Ser Ile Val Met Pro Val 
65                  70                  75                  80  


Gly Gly Gln Ser Ser Phe Tyr Ser Asp Trp Tyr Ser Pro Ala Cys Gly 
                85                  90                  95      


Lys Ala Gly Cys Gln Thr Tyr Lys Trp Glu Thr Phe Leu Thr Ser Glu 
            100                 105                 110         


Leu Pro Gln Trp Leu Ser Ala Asn Arg Ala Val Lys Pro Thr Gly Ser 
        115                 120                 125             


Ala Ala Ile Gly Leu Ser Met Ala Gly Ser Ser Ala Met Ile Leu Ala 
    130                 135                 140                 


Ala Tyr His Pro Gln Gln Phe Ile Tyr Ala Gly Ser Leu Ser Ala Leu 
145                 150                 155                 160 


Leu Asp Pro Ser Gln Gly Met Gly Pro Ser Leu Ile Gly Leu Ala Met 
                165                 170                 175     


Gly Asp Ala Gly Gly Tyr Lys Ala Ala Asp Met Trp Gly Pro Ser Ser 
            180                 185                 190         


Asp Pro Ala Trp Glu Arg Asn Asp Pro Thr Gln Gln Ile Pro Lys Leu 
        195                 200                 205             


Val Ala Asn Asn Thr Arg Leu Trp Val Tyr Cys Gly Asn Gly Thr Pro 
    210                 215                 220                 


Asn Glu Leu Gly Gly Ala Asn Ile Pro Ala Glu Phe Leu Glu Asn Phe 
225                 230                 235                 240 


Val Arg Ser Ser Asn Leu Lys Phe Gln Asp Ala Tyr Asn Ala Ala Gly 
                245                 250                 255     


Gly His Asn Ala Val Phe Asn Phe Pro Pro Asn Gly Thr His Ser Trp 
            260                 265                 270         


Glu Tyr Trp Gly Ala Gln Leu Asn Ala Met Lys Gly Asp Leu Gln Ser 
        275                 280                 285             


Ser Leu Gly Ala Gly 
    290             


<210>  5
<211>  22
<212>  PRT
<213>  artificial sequence

<220>
<223>  isolated cleavage site F2A of the foot and mouth disease virus

<400>  5

Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val 
1               5                   10                  15      


Glu Ser Asn Pro Gly Pro 
            20          


<210>  6
<211>  18
<212>  PRT
<213>  artificial sequence

<220>
<223>  isolated cleavage site 2A peptide of the Thosea asigna virus

<400>  6

Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro 
1               5                   10                  15      


Gly Pro 
        


<210>  7
<211>  20
<212>  PRT
<213>  artificial sequence

<220>
<223>  isolated cleavge site 2A peptide of Equine rhinitis A virus

<400>  7

Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp Val Glu Ser 
1               5                   10                  15      


Asn Pro Gly Pro 
            20  


<210>  8
<211>  357
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion of modified RpfB and RpfD resuscitation Mtb antigens

<400>  8

Met Thr Val Asp Gly Thr Ala Met Arg Val Thr Thr Met Lys Ser Arg 
1               5                   10                  15      


Val Ile Asp Ile Val Glu Glu Asn Gly Phe Ser Val Asp Asp Arg Asp 
            20                  25                  30          


Asp Leu Tyr Pro Ala Ala Gly Val Gln Val His Asp Ala Asp Thr Ile 
        35                  40                  45              


Val Leu Arg Arg Ser Arg Pro Leu Gln Ile Ser Leu Asp Gly His Asp 
    50                  55                  60                  


Ala Lys Gln Val Trp Thr Thr Ala Ser Thr Val Asp Glu Ala Leu Ala 
65                  70                  75                  80  


Gln Leu Ala Met Thr Asp Thr Ala Pro Ala Ala Ala Ser Arg Ala Ser 
                85                  90                  95      


Arg Val Pro Leu Ser Gly Met Ala Leu Pro Val Val Ser Ala Lys Thr 
            100                 105                 110         


Val Gln Leu Asn Asp Gly Gly Leu Val Arg Thr Val His Leu Pro Ala 
        115                 120                 125             


Pro Asn Val Ala Gly Leu Leu Ser Ala Ala Gly Val Pro Leu Leu Gln 
    130                 135                 140                 


Ser Asp His Val Val Pro Ala Ala Thr Ala Pro Ile Val Glu Gly Met 
145                 150                 155                 160 


Gln Ile Gln Val Thr Arg Asn Arg Ile Lys Lys Val Thr Glu Arg Leu 
                165                 170                 175     


Pro Leu Pro Pro Asn Ala Arg Arg Val Glu Asp Pro Glu Met Asn Met 
            180                 185                 190         


Ser Arg Glu Val Val Glu Asp Pro Gly Val Pro Gly Thr Gln Asp Val 
        195                 200                 205             


Thr Phe Ala Val Ala Glu Val Asn Gly Val Glu Thr Gly Arg Leu Pro 
    210                 215                 220                 


Val Ala Asn Val Val Val Thr Pro Ala His Glu Ala Val Val Arg Val 
225                 230                 235                 240 


Gly Thr Lys Pro Gly Thr Glu Val Pro Pro Val Ile Asp Gly Ser Ile 
                245                 250                 255     


Trp Asp Ala Ile Ala Gln Cys Lys Ser Gly Gly Asn Trp Ala Ala Asn 
            260                 265                 270         


Thr Gly Asn Gly Leu Tyr Gly Gly Leu Gln Ile Ser Gln Ala Ala Trp 
        275                 280                 285             


Asp Ser Asn Gly Gly Val Gly Ser Pro Ala Ala Ala Ser Pro Gln Gln 
    290                 295                 300                 


Gln Ile Glu Val Ala Asp Asn Ile Met Lys Thr Ala Gly Pro Gly Ala 
305                 310                 315                 320 


Trp Pro Lys Cys Ser Ser Cys Ser Gln Gly Asp Ala Pro Leu Gly Ser 
                325                 330                 335     


Leu Thr His Ile Leu Thr Phe Leu Ala Ala Glu Thr Gly Gly Cys Ser 
            340                 345                 350         


Gly Ser Arg Asp Asp 
        355         


<210>  9
<211>  457
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion of Rv2626 with Ag85B** Mtb antigens with F2A cleavage site
       in between

<400>  9

Met Thr Thr Ala Arg Asp Ile Met Asn Ala Gly Val Thr Cys Val Gly 
1               5                   10                  15      


Glu His Glu Thr Leu Thr Ala Ala Ala Gln Tyr Met Arg Glu His Asp 
            20                  25                  30          


Ile Gly Ala Leu Pro Ile Cys Gly Asp Asp Asp Arg Leu His Gly Met 
        35                  40                  45              


Leu Thr Asp Arg Asp Ile Val Ile Lys Gly Leu Ala Ala Gly Leu Asp 
    50                  55                  60                  


Pro Asn Thr Ala Thr Ala Gly Glu Leu Ala Arg Asp Ser Ile Tyr Tyr 
65                  70                  75                  80  


Val Asp Ala Asn Ala Ser Ile Gln Glu Met Leu Asn Val Met Glu Glu 
                85                  90                  95      


His Gln Val Arg Arg Val Pro Val Ile Ser Glu His Arg Leu Val Gly 
            100                 105                 110         


Ile Val Thr Glu Ala Asp Ile Ala Arg His Leu Pro Glu His Ala Ile 
        115                 120                 125             


Val Gln Phe Val Lys Ala Ile Cys Ser Pro Met Ala Leu Ala Ser Gly 
    130                 135                 140                 


Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu 
145                 150                 155                 160 


Asn Pro Gly Pro Gly Gly Ala Ala Thr Ala Gly Ala Phe Ser Arg Pro 
                165                 170                 175     


Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser Pro Ser Met Gly Arg 
            180                 185                 190         


Asp Ile Lys Val Gln Phe Gln Ser Gly Gly Asn Asn Ser Pro Ala Val 
        195                 200                 205             


Tyr Leu Leu Asp Gly Leu Arg Ala Gln Asp Asp Tyr Asn Gly Trp Asp 
    210                 215                 220                 


Ile Asn Thr Pro Ala Phe Glu Trp Tyr Tyr Gln Ser Gly Leu Ser Ile 
225                 230                 235                 240 


Val Met Pro Val Gly Gly Gln Ser Ser Phe Tyr Ser Asp Trp Tyr Ser 
                245                 250                 255     


Pro Ala Cys Gly Lys Ala Gly Cys Gln Thr Tyr Lys Trp Glu Thr Phe 
            260                 265                 270         


Leu Thr Ser Glu Leu Pro Gln Trp Leu Ser Ala Asn Arg Ala Val Lys 
        275                 280                 285             


Pro Thr Gly Ser Ala Ala Ile Gly Leu Ser Met Ala Gly Ser Ser Ala 
    290                 295                 300                 


Met Ile Leu Ala Ala Tyr His Pro Gln Gln Phe Ile Tyr Ala Gly Ser 
305                 310                 315                 320 


Leu Ser Ala Leu Leu Asp Pro Ser Gln Gly Met Gly Pro Ser Leu Ile 
                325                 330                 335     


Gly Leu Ala Met Gly Asp Ala Gly Gly Tyr Lys Ala Ala Asp Met Trp 
            340                 345                 350         


Gly Pro Ser Ser Asp Pro Ala Trp Glu Arg Asn Asp Pro Thr Gln Gln 
        355                 360                 365             


Ile Pro Lys Leu Val Ala Asn Asn Thr Arg Leu Trp Val Tyr Cys Gly 
    370                 375                 380                 


Asn Gly Thr Pro Asn Glu Leu Gly Gly Ala Asn Ile Pro Ala Glu Phe 
385                 390                 395                 400 


Leu Glu Asn Phe Val Arg Ser Ser Asn Leu Lys Phe Gln Asp Ala Tyr 
                405                 410                 415     


Asn Ala Ala Gly Gly His Asn Ala Val Phe Asn Phe Pro Pro Asn Gly 
            420                 425                 430         


Thr His Ser Trp Glu Tyr Trp Gly Ala Gln Leu Asn Ala Met Lys Gly 
        435                 440                 445             


Asp Leu Gln Ser Ser Leu Gly Ala Gly 
    450                 455         


<210>  10
<211>  436
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion of Rv2626 and Ag85B** Mtb antigens

<400>  10

Met Thr Thr Ala Arg Asp Ile Met Asn Ala Gly Val Thr Cys Val Gly 
1               5                   10                  15      


Glu His Glu Thr Leu Thr Ala Ala Ala Gln Tyr Met Arg Glu His Asp 
            20                  25                  30          


Ile Gly Ala Leu Pro Ile Cys Gly Asp Asp Asp Arg Leu His Gly Met 
        35                  40                  45              


Leu Thr Asp Arg Asp Ile Val Ile Lys Gly Leu Ala Ala Gly Leu Asp 
    50                  55                  60                  


Pro Asn Thr Ala Thr Ala Gly Glu Leu Ala Arg Asp Ser Ile Tyr Tyr 
65                  70                  75                  80  


Val Asp Ala Asn Ala Ser Ile Gln Glu Met Leu Asn Val Met Glu Glu 
                85                  90                  95      


His Gln Val Arg Arg Val Pro Val Ile Ser Glu His Arg Leu Val Gly 
            100                 105                 110         


Ile Val Thr Glu Ala Asp Ile Ala Arg His Leu Pro Glu His Ala Ile 
        115                 120                 125             


Val Gln Phe Val Lys Ala Ile Cys Ser Pro Met Ala Leu Ala Ser Gly 
    130                 135                 140                 


Gly Ala Ala Thr Ala Gly Ala Phe Ser Arg Pro Gly Leu Pro Val Glu 
145                 150                 155                 160 


Tyr Leu Gln Val Pro Ser Pro Ser Met Gly Arg Asp Ile Lys Val Gln 
                165                 170                 175     


Phe Gln Ser Gly Gly Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp Gly 
            180                 185                 190         


Leu Arg Ala Gln Asp Asp Tyr Asn Gly Trp Asp Ile Asn Thr Pro Ala 
        195                 200                 205             


Phe Glu Trp Tyr Tyr Gln Ser Gly Leu Ser Ile Val Met Pro Val Gly 
    210                 215                 220                 


Gly Gln Ser Ser Phe Tyr Ser Asp Trp Tyr Ser Pro Ala Cys Gly Lys 
225                 230                 235                 240 


Ala Gly Cys Gln Thr Tyr Lys Trp Glu Thr Phe Leu Thr Ser Glu Leu 
                245                 250                 255     


Pro Gln Trp Leu Ser Ala Asn Arg Ala Val Lys Pro Thr Gly Ser Ala 
            260                 265                 270         


Ala Ile Gly Leu Ser Met Ala Gly Ser Ser Ala Met Ile Leu Ala Ala 
        275                 280                 285             


Tyr His Pro Gln Gln Phe Ile Tyr Ala Gly Ser Leu Ser Ala Leu Leu 
    290                 295                 300                 


Asp Pro Ser Gln Gly Met Gly Pro Ser Leu Ile Gly Leu Ala Met Gly 
305                 310                 315                 320 


Asp Ala Gly Gly Tyr Lys Ala Ala Asp Met Trp Gly Pro Ser Ser Asp 
                325                 330                 335     


Pro Ala Trp Glu Arg Asn Asp Pro Thr Gln Gln Ile Pro Lys Leu Val 
            340                 345                 350         


Ala Asn Asn Thr Arg Leu Trp Val Tyr Cys Gly Asn Gly Thr Pro Asn 
        355                 360                 365             


Glu Leu Gly Gly Ala Asn Ile Pro Ala Glu Phe Leu Glu Asn Phe Val 
    370                 375                 380                 


Arg Ser Ser Asn Leu Lys Phe Gln Asp Ala Tyr Asn Ala Ala Gly Gly 
385                 390                 395                 400 


His Asn Ala Val Phe Asn Phe Pro Pro Asn Gly Thr His Ser Trp Glu 
                405                 410                 415     


Tyr Trp Gly Ala Gln Leu Asn Ala Met Lys Gly Asp Leu Gln Ser Ser 
            420                 425                 430         


Leu Gly Ala Gly 
        435     


<210>  11
<211>  235
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion of Rv3407 and Rv1813** Mtb antigens with E2A cleavage site
       in between

<400>  11

Met Arg Ala Thr Val Gly Leu Val Glu Ala Ile Gly Ile Arg Glu Leu 
1               5                   10                  15      


Arg Gln His Ala Ser Arg Tyr Leu Ala Arg Val Glu Ala Gly Glu Glu 
            20                  25                  30          


Leu Gly Val Thr Asn Lys Gly Arg Leu Val Ala Arg Leu Ile Pro Val 
        35                  40                  45              


Gln Ala Ala Glu Arg Ser Arg Glu Ala Leu Ile Glu Ser Gly Val Leu 
    50                  55                  60                  


Ile Pro Ala Arg Arg Pro Gln Asn Leu Leu Asp Val Thr Ala Glu Pro 
65                  70                  75                  80  


Ala Arg Gly Arg Lys Arg Thr Leu Ser Asp Val Leu Asn Glu Met Arg 
                85                  90                  95      


Asp Glu Gln Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu 
            100                 105                 110         


Ala Gly Asp Val Glu Ser Asn Pro Gly Pro Asp Ala His Leu Ala Asn 
        115                 120                 125             


Gly Ser Met Ser Glu Val Met Met Ser Glu Ile Ala Gly Leu Pro Ile 
    130                 135                 140                 


Pro Pro Ile Ile His Tyr Gly Ala Ile Ala Tyr Ala Pro Ser Gly Ala 
145                 150                 155                 160 


Ser Gly Lys Ala Trp His Gln Arg Thr Pro Ala Arg Ala Glu Gln Val 
                165                 170                 175     


Ala Leu Glu Lys Cys Gly Asp Lys Thr Cys Lys Val Val Ser Arg Phe 
            180                 185                 190         


Thr Arg Cys Gly Ala Val Ala Tyr Asn Gly Ser Lys Tyr Gln Gly Gly 
        195                 200                 205             


Thr Gly Leu Thr Arg Arg Ala Ala Glu Asp Asp Ala Val Asn Arg Leu 
    210                 215                 220                 


Glu Gly Gly Arg Ile Val Asn Trp Ala Cys Asn 
225                 230                 235 


<210>  12
<211>  212
<212>  PRT
<213>  artificial sequence

<220>
<223>  fusion of Rv3407 and Rv1813* Mtb antigens

<400>  12

Met Arg Ala Thr Val Gly Leu Val Glu Ala Ile Gly Ile Arg Glu Leu 
1               5                   10                  15      


Arg Gln His Ala Ser Arg Tyr Leu Ala Arg Val Glu Ala Gly Glu Glu 
            20                  25                  30          


Leu Gly Val Thr Asn Lys Gly Arg Leu Val Ala Arg Leu Ile Pro Val 
        35                  40                  45              


Gln Ala Ala Glu Arg Ser Arg Glu Ala Leu Ile Glu Ser Gly Val Leu 
    50                  55                  60                  


Ile Pro Ala Arg Arg Pro Gln Asn Leu Leu Asp Val Thr Ala Glu Pro 
65                  70                  75                  80  


Ala Arg Gly Arg Lys Arg Thr Leu Ser Asp Val Leu Asn Glu Met Arg 
                85                  90                  95      


Asp Glu Gln Asp Ala His Leu Ala Asn Gly Ser Met Ser Glu Val Met 
            100                 105                 110         


Met Ser Glu Ile Ala Gly Leu Pro Ile Pro Pro Ile Ile His Tyr Gly 
        115                 120                 125             


Ala Ile Ala Tyr Ala Pro Ser Gly Ala Ser Gly Lys Ala Trp His Gln 
    130                 135                 140                 


Arg Thr Pro Ala Arg Ala Glu Gln Val Ala Leu Glu Lys Cys Gly Asp 
145                 150                 155                 160 


Lys Thr Cys Lys Val Val Ser Arg Phe Thr Arg Cys Gly Ala Val Ala 
                165                 170                 175     


Tyr Asn Gly Ser Lys Tyr Gln Gly Gly Thr Gly Leu Thr Arg Arg Ala 
            180                 185                 190         


Ala Glu Asp Asp Ala Val Asn Arg Leu Glu Gly Gly Arg Ile Val Asn 
        195                 200                 205             


Trp Ala Cys Asn 
    210         


<210>  13
<211>  637
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence encoding the fusion of CFP10 with its partner ESAT6

<400>  13
accatggccg agatgaagac cgatgccgcc accctggctc aggaagccgg caacttcgag       60

agaatcagcg gcgacctgaa aacccagatc gaccaggtgg aaagcaccgc cggatctctg      120

cagggacagt ggcggggagc tgctggaaca gctgctcagg ctgctgtcgt gcggtttcag      180

gaagctgcca acaagcagaa gcaggaactg gacgagatca gcaccaacat ccggcaggcc      240

ggcgtgcagt acagcagagc cgatgaggaa cagcagcagg ccctgtccag ccagatgggc      300

tttggaccta agcagggcga ggatgatggc tctacaggcg gccctaccga gcagcagtgg      360

aacttcgccg gaattgaggc cgctgccagc gccatccagg gcaacgtgac atccatccac      420

agcctgctgg acgagggcaa gcagagcctg acaaaactgg ctgctgcctg gggcggctct      480

ggctctgaag cttatcaggg cgtgcagcag aagtgggacg ccaccgccac cgagctgaac      540

aacgccctgc agaacctggc ccggacaatc tctgaagccg gacaggccat ggccagcacc      600

gagggcaatg tgaccggcat gtttgcctaa tttttgt                               637


<210>  14
<211>  628
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for the fusion of TB10.4 Mtb antigen with its 
       partner TB9.8 (Rv0287)

<400>  14
accatgagcc agatcatgta caactacccc gccatgctgg gccacgccgg cgatatggct       60

ggatatgccg gcacactgca gagcctgggt gccgagattg ccgtggaaca ggctgccctc      120

cagtctgcct ggcagggcga taccggcatc acataccagg cttggcaggc ccagtggaac      180

caggccatgg aagatctcgt gcgggcctac cacgccatga gcagcacaca cgaggccaac      240

accatggcca tgatggcccg ggatacagcc gaggccgcta agtggggagg aggccccaaa      300

caaggagaag atgacggcag caccggagga agtctgctcg acgcccacat ccctcagctc      360

gtggctagcc agtctgcctt tgccgccaaa gccggcctga tgagacacac cattggccag      420

gccgaacagg ccgccatgtc tgcccaggct tttcaccagg gcgaaagcag cgccgccttt      480

caggccgccc atgccagatt tgtggccgct gccgctaaag tgaacaccct cctggacgtg      540

gcccaggcca atctgggaga agccgccgga acttacgtgg ccgcagatgc cgctgctgcc      600

agcacctaca caggcttcta gtttttct                                         628


<210>  15
<211>  1084
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for the fusion of mutant RpfB and RpfD Mtb 
       antigens

<400>  15
accatgaccg tggacggcac cgccatgaga gtgaccacca tgaagtccag agtgatcgac       60

atcgtggaag agaacggctt cagcgtggac gaccgggacg acctgtatcc tgctgctgga      120

gtgcaggtcc acgacgccga tacaatcgtg ctgcggagaa gcagacccct gcagatcagc      180

ctggatggcc acgacgccaa gcaggtctgg accacagcca gcacagtgga tgaagccctg      240

gcccagctgg ccatgaccga tacagctcca gccgccgcta gcagagctag cagagtgcct      300

ctgtctggca tggccctgcc tgtggtgtct gccaagaccg tgcagctgaa cgatggcggc      360

ctcgtgcgga cagtgcatct gcctgctcct aatgtggccg gcctgctgtc tgcagcaggc      420

gtgccactgc tgcagagcga tcatgtggtg cctgccgcca cagcccctat cgtggaaggc      480

atgcagatcc aggtcacacg gaaccggatc aagaaagtga ccgagcggct gcccctgcct      540

cccaacgcta gaagagtgga agatcccgag atgaacatga gcagagaggt ggtcgaggac      600

cctggcgtgc caggcacaca ggatgtgaca ttcgccgtgg ccgaagtgaa cggcgtggaa      660

accggcagac tgcccgtggc caatgtggtg gtcacaccag cccatgaggc cgtcgtcaga      720

gtgggcacaa agcctggcac agaggtgcca cccgtgatcg acggcagcat ctgggatgcc      780

attgcccagt gcaagagcgg cggaaactgg gccgccaata ccggcaatgg cctctatggc      840

ggcctgcaga tctctcaggc cgcctgggat tctaatggcg gcgtgggatc tcctgccgct      900

gcctctccac agcagcagat cgaggtggcc gacaacatca tgaagacagc cggacctggc      960

gcctggccca agtgtagcag ttgttctcag ggcgacgccc ctctgggcag cctgacacac     1020

atcctgacat ttctggccgc cgagacaggc ggatgtagcg gctctagaga tgactagttt     1080

ttct                                                                  1084


<210>  16
<211>  1384
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for the fusion of Rv2626 with Ag85B** Mtb 
       antigens with peptide 2A cleavage site in between

<400>  16
accatgacaa ccgccagaga catcatgaac gccggcgtga cctgtgtggg cgagcacgag       60

acactgacag ccgccgctca gtacatgaga gagcacgaca tcggcgccct gcccatctgc      120

ggcgacgatg atagactgca cggcatgctg accgaccggg acatcgtgat caagggcctg      180

gctgctggcc tggaccccaa tactgctaca gctggcgagc tggcaagaga cagcatctac      240

tacgtggacg ccaacgccag catccaggaa atgctgaacg tgatggaaga acaccaggtc      300

cgacgggtgc ccgtgatcag cgaacacaga ctcgtgggca tcgtgaccga ggccgatatc      360

gccagacatc tgcccgagca cgccatcgtg cagttcgtga aggccatctg cagccccatg      420

gccctggcct ctggcagcgg agagggcaga ggcagcctgc tgacatgtgg tgacgtagag      480

gagaatccag gacctggcgg agctgctaca gccggcgcct tctctagacc tggcctgccc      540

gtggaatacc tgcaggtccc aagccccagc atgggccggg atatcaaggt gcagtttcag      600

agcggcggca acaacagccc tgccgtgtat ctgctggatg gcctgagagc ccaggacgac      660

tacaacggct gggacatcaa cacccctgcc ttcgagtggt actaccagag cggcctgtcc      720

atcgtgatgc ctgtgggcgg ccagagcagc ttctacagcg actggtacag ccccgcctgt      780

ggcaaagccg gctgccagac ctacaagtgg gagacattcc tgacctccga gctgccccag      840

tggctgagcg ccaatagagc cgtgaagcct acaggctctg ccgccatcgg actgagcatg      900

gccggaagct ctgccatgat cctggccgcc tatcaccctc agcagttcat ctacgccggc      960

agcctgtctg ccctgctgga cccttctcag ggcatgggcc cttctctgat cggactggct     1020

atgggcgacg ctggcggata caaggccgcc gatatgtggg gccctagcag cgatcctgcc     1080

tgggagagaa acgaccccac ccagcagatc cccaagctgg tggccaacaa cacccggctg     1140

tgggtgtact gcggcaacgg cacccctaat gaactgggcg gagccaatat ccccgccgag     1200

ttcctggaaa acttcgtgcg gagcagcaac ctgaagttcc aggatgccta caacgccgct     1260

ggcggccaca acgccgtgtt caacttccct cccaatggca cccacagctg ggagtactgg     1320

ggagcccagc tgaacgccat gaagggcgat ctgcagtcct ctctgggagc cggctaattt     1380

ttct                                                                  1384


<210>  17
<211>  1321
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for the fusion of Rv2626 with Ag85B** Mtb 
       antigens

<400>  17
accatgacaa ccgccagaga catcatgaac gccggcgtga cctgtgtggg cgagcacgag       60

acactgacag ccgccgctca gtacatgaga gagcacgaca tcggcgccct gcccatctgc      120

ggcgacgatg atagactgca cggcatgctg accgaccggg acatcgtgat caagggcctg      180

gctgctggcc tggaccccaa tactgctaca gctggcgagc tggcaagaga cagcatctac      240

tacgtggacg ccaacgccag catccaggaa atgctgaacg tgatggaaga acaccaggtc      300

cgacgggtgc ccgtgatcag cgaacacaga ctcgtgggca tcgtgaccga ggccgatatc      360

gccagacatc tgcccgagca cgccatcgtg cagttcgtga aggccatctg cagccccatg      420

gccctggcct ctggcggagc tgctacagcc ggcgccttct ctagacctgg cctgcccgtg      480

gaatacctgc aggtcccaag ccccagcatg ggccgggata tcaaggtgca gtttcagagc      540

ggcggcaaca acagccctgc cgtgtatctg ctggatggcc tgagagccca ggacgactac      600

aacggctggg acatcaacac ccctgccttc gagtggtact accagagcgg cctgtccatc      660

gtgatgcctg tgggcggcca gagcagcttc tacagcgact ggtacagccc cgcctgtggc      720

aaagccggct gccagaccta caagtgggag acattcctga cctccgagct gccccagtgg      780

ctgagcgcca atagagccgt gaagcctaca ggctctgccg ccatcggact gagcatggcc      840

ggaagctctg ccatgatcct ggccgcctat caccctcagc agttcatcta cgccggcagc      900

ctgtctgccc tgctggaccc ttctcagggc atgggccctt ctctgatcgg actggctatg      960

ggcgacgctg gcggatacaa ggccgccgat atgtggggcc ctagcagcga tcctgcctgg     1020

gagagaaacg accccaccca gcagatcccc aagctggtgg ccaacaacac ccggctgtgg     1080

gtgtactgcg gcaacggcac ccctaatgaa ctgggcggag ccaatatccc cgccgagttc     1140

ctggaaaact tcgtgcggag cagcaacctg aagttccagg atgcctacaa cgccgctggc     1200

ggccacaacg ccgtgttcaa cttccctccc aatggcaccc acagctggga gtactgggga     1260

gcccagctga acgccatgaa gggcgatctg cagtcctctc tgggagccgg ctaatttttc     1320

t                                                                     1321


<210>  18
<211>  718
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for the fusion of Rv3407 and Rv1813** Mtb 
       antigens with peptide 2A in between

<400>  18
accatgagag ccaccgtggg actggtggaa gccatcggca tcagagagct gagacagcac       60

gccagcagat acctggccag agtggaagcc ggcgaggaac tgggcgtgac caacaagggc      120

agactggtgg ccagactgat ccctgtgcag gccgccgaga gaagcagaga ggccctgatt      180

gagagcggcg tgctgatccc tgccagacgg cctcagaacc tgctggatgt gacagccgag      240

cccgccagag gccggaagag aaccctgagc gacgtgctga acgagatgcg ggatgaacag      300

gggtcaggac agtgcaccaa ctacgctctc ctgaaactgg ccggcgatgt ggaaagcaac      360

cctggccctg atgcccatct ggccaacggc agcatgagcg aagtgatgat gagcgagatc      420

gccggcctgc ccatccctcc catcatccac tatggcgcca ttgcctacgc ccctagcggc      480

gcctctggaa aagcttggca tcagagaaca cccgccagag ccgaacaggt ggccctggaa      540

aagtgcggcg acaagacctg caaggtggtg tcccggttca ccagatgtgg cgccgtggcc      600

tacaacggct ccaagtatca gggcggcacc ggcctgacaa gaagggccgc tgaggacgac      660

gccgtgaaca ggctggaggg aggcagaatc gtgaactggg cctgcaacta atttttct        718


<210>  19
<211>  649
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding fro the fusion of Rv3407 and Rv1813* Mtb 
       antigens

<400>  19
accatgagag ccaccgtggg actggtggaa gccatcggca tcagagagct gagacagcac       60

gccagcagat acctggccag agtggaagcc ggcgaggaac tgggcgtgac caacaagggc      120

agactggtgg ccagactgat ccctgtgcag gccgccgaga gaagcagaga ggccctgatt      180

gagagcggcg tgctgatccc tgccagacgg cctcagaacc tgctggatgt gacagccgag      240

cccgccagag gccggaagag aaccctgagc gacgtgctga acgagatgcg ggatgaacag      300

gatgcccatc tggccaacgg cagcatgagc gaagtgatga tgagcgagat cgccggcctg      360

cccatccctc ccatcatcca ctatggcgcc attgcctacg cccctagcgg cgcctctgga      420

aaagcttggc atcagagaac acccgccaga gccgaacagg tggccctgga aaagtgcggc      480

gacaagacct gcaaggtggt gtcccggttc accagatgtg gcgccgtggc ctacaacggc      540

tccaagtatc agggcggcac cggcctgaca agaagggccg ctgaggacga cgccgtgaac      600

aggctggagg gaggcagaat cgtgaactgg gcctgcaact aatttttct                  649


<210>  20
<211>  100
<212>  DNA
<213>  Vaccinia virus

<400>  20
tatattatta agtgtggtgt ttggtcgatg taaaattttt gtcgataaaa attaaaaaat       60

aacttaattt attattgatc tcgtgtgtac aaccgaaatc                            100


<210>  21
<211>  114
<212>  DNA
<213>  Vaccinia virus

<400>  21
tttattctat acttaaaaaa tgaaaataaa tacaaaggtt cttgagggtt gtgttaaatt       60

gaaagcgaga aataatcata aattatttca ttatcgcgat atccgttaag tttg            114


<210>  22
<211>  40
<212>  DNA
<213>  artificial sequence

<220>
<223>  early late promoter of vaccinia virus

<400>  22
aaaaattgaa attttatttt ttttttttgg aatataaata                             40


<210>  23
<211>  124
<212>  DNA
<213>  Vaccinia virus

<400>  23
ccacccactt tttatagtaa gtttttcacc cataaataat aaatacaata attaatttct       60

cgtaaaagta gaaaatatat tctaatttat tgcacggtaa ggaagtagaa tcataaagaa      120

cagt                                                                   124


<210>  24
<211>  50
<212>  DNA
<213>  Vaccinia virus

<400>  24
caagtgacaa caaaaaatga attaataata agtcgttaac gtacgccgcc                  50


<210>  25
<211>  298
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  25
accatgaccg agcagcagtg gaacttcgcc ggaattgagg ccgctgccag cgccatccag       60

ggcaacgtga catccatcca cagcctgctg gacgagggca agcagagcct gacaaaactg      120

gctgctgcct ggggcggctc tggctctgaa gcttatcagg gcgtgcagca gaagtgggac      180

gccaccgcca ccgagctgaa caacgccctg cagaacctgg cccggacaat ctctgaagcc      240

ggacaggcca tggccagcac cgagggcaat gtgaccggca tgtttgcctg atttttct        298


<210>  26
<211>  313
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  26
accatggccg agatgaagac cgatgccgcc accctggctc aggaagccgg caacttcgag       60

agaatcagcg gcgacctgaa aacccagatc gaccaggtgg aaagcaccgc cggatctctg      120

cagggacagt ggcggggagc tgctggaaca gctgctcagg ctgctgtcgt gcggtttcag      180

gaagctgcca acaagcagaa gcaggaactg gacgagatca gcaccaacat ccggcaggcc      240

ggcgtgcagt acagcagagc cgatgaggaa cagcagcagg ccctgtccag ccagatgggc      300

ttttgatttt tgt                                                         313


<210>  27
<211>  442
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  27
accatgacaa ccgccagaga catcatgaac gccggcgtga cctgtgtggg cgagcacgag       60

acactgacag ccgccgctca gtacatgaga gagcacgaca tcggcgccct gcccatctgc      120

ggcgacgatg atagactgca cggcatgctg accgaccggg acatcgtgat caagggcctg      180

gctgctggcc tggaccccaa tactgctaca gctggcgagc tggcaagaga cagcatctac      240

tacgtggacg ccaacgccag catccaggaa atgctgaacg tgatggaaga acaccaggtc      300

cgacgggtgc ccgtgatcag cgaacacaga ctcgtgggca tcgtgaccga ggccgatatc      360

gccagacatc tgcccgagca cgccatcgtg cagttcgtga aggccatctg cagccccatg      420

gccctggcct cttgattttt ct                                               442


<210>  28
<211>  874
<212>  DNA
<213>  artificial sequence

<220>
<223>  nt sequence coding for mutant Ag85B* Mtb antigen

<400>  28
accatggcct tctctagacc tggcctgccc gtggaatacc tgcaggtccc aagccccagc       60

atgggccggg atatcaaggt gcagtttcag agcggcggca acaacagccc tgccgtgtat      120

ctgctggatg gcctgagagc ccaggacgac tacaacggct gggacatcaa cacccctgcc      180

ttcgagtggt actaccagag cggcctgtcc atcgtgatgc ctgtgggcgg ccagagcagc      240

ttctacagcg actggtacag ccccgcctgt ggcaaagccg gctgccagac ctacaagtgg      300

gagacattcc tgacctccga gctgccccag tggctgagcg ccaatagagc cgtgaagcct      360

acaggctctg ccgccatcgg actgagcatg gccggaagct ctgccatgat cctggccgcc      420

tatcaccctc agcagttcat ctacgccggc agcctgtctg ccctgctgga cccttctcag      480

ggcatgggcc cttctctgat cggactggct atgggcgacg ctggcggata caaggccgcc      540

gatatgtggg gccctagcag cgatcctgcc tgggagagaa acgaccccac ccagcagatc      600

cccaagctgg tggccaacaa cacccggctg tgggtgtact gcggcaacgg cacccctaat      660

gaactgggcg gagccaatat ccccgccgag ttcctggaaa acttcgtgcg gagcagcaac      720

ctgaagttcc aggatgccta caacgccgct ggcggccaca acgccgtgtt caacttccct      780

cccaatggca cccacagctg ggagtactgg ggagcccagc tgaacgccat gaagggcgat      840

ctgcagtcct ctctgggagc cggctgattt ttgt                                  874


<210>  29
<211>  304
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  29
accatgagcc tgctggacgc ccacatccct cagctggtgg ccagccagtc tgcctttgcc       60

gccaaagccg gcctgatgag acacaccatt ggccaggccg aacaggccgc catgtctgcc      120

caggcttttc accagggcga aagcagcgcc gcctttcagg ccgcccatgc cagatttgtg      180

gccgctgccg ctaaagtgaa caccctgctg gatgtggccc aggccaatct gggagaagcc      240

gccggaactt acgtggccgc agatgccgct gctgccagca cctacacagg cttctgattt      300

ttct                                                                   304


<210>  30
<211>  301
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  30
accatgagcc agatcatgta caactacccc gccatgctgg gccacgccgg cgatatggct       60

ggatatgccg gcacactgca gagcctgggt gccgagattg ccgtggaaca ggctgccctc      120

cagtctgcct ggcagggcga taccggcatc acataccagg cttggcaggc ccagtggaac      180

caggccatgg aagatctcgt gcgggcctac cacgccatga gcagcacaca cgaggccaac      240

accatggcca tgatggcccg ggatacagcc gaggccgcta agtggggagg ataatttttc      300

t                                                                      301


<210>  31
<211>  310
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  31
accatgagag ccaccgtggg actggtggaa gccatcggca tcagagagct gagacagcac       60

gccagcagat acctggccag agtggaagcc ggcgaggaac tgggcgtgac caacaagggc      120

agactggtgg ccagactgat ccctgtgcag gccgccgaga gaagcagaga ggccctgatt      180

gagagcggcg tgctgatccc tgccagacgg cctcagaacc tgctggatgt gacagccgag      240

cccgccagag gccggaagag aaccctgagc gacgtgctga acgagatgcg ggatgaacag      300

taatttttct                                                             310


<210>  32
<211>  1192
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  32
accatggtgg acttcggcgc cctgcctccc gagattaata gcgccaggat gtacgccggc       60

cctggcagcg cttctctggt ggccgctgcc aagatgtggg atagcgtggc cagcgacctg      120

ttctctgccg ccagcgcatt tcagagcgtc gtgtggggac tcactgtggg ctcttggatc      180

ggatcttctg ccggtctgat ggccgctgct gcctctcctt atgtggcctg gatgagcgtg      240

accgccggac aggcacagct gacagctgca caggtccgag tggctgccgc cgcttacgag      300

acagcctaca gactgacagt gcctccaccc gtgatcgccg agaatcggac cgagctcatg      360

accctgaccg ccaccaatct gctcggccag aacacccctg ccatcgaggc caatcaggcc      420

gcctactctc aaatgtgggg ccaagatgcc gaggctatgt acggctatgc agccacagcc      480

gccactgcta cagaagccct gctgcccttc gaagatgccc ctctgatcac aaaccctggc      540

ggcctgctgg aacaggccgt ggctgtggaa gaggccatcg ataccgctgc cgccaaccaa      600

ctcatgaaca acgtgccaca ggccctccag cagctggctc agcctgctca gggcgtggtg      660

ccttctagca agctcggcgg actgtggacc gccgtgtctc ctcatctgag ccctctgagc      720

aacgtgtcct ctatcgccaa caaccacatg agcatgatgg gcaccggcgt gtccatgacc      780

aacaccctgc acagcatgct gaagggactg gcccctgctg ctgcccaggc tgtggaaaca      840

gccgccgaaa atggcgtgtg ggccatgagc agcctgggct ctcagctggg aagctccctc      900

ggttcttctg gactgggagc tggcgtggcc gccaatctgg gaagagctgc ttctgtcggc      960

agcctgtctg tgcctcctgc ttgggccgct gctaaccagg ctgtgacacc agctgctaga     1020

gccctgcctc tgaccagcct gacatctgcc gctcagacag cccctggcca catgctggga     1080

ggactgcctc tgggccactc tgtgaatgcc ggcagcggca tcaacaacgc cctgagagtg     1140

cctgccagag cctacgccat ccccagaact ccagccgctg gctaattttt gt             1192


<210>  33
<211>  307
<212>  DNA
<213>  Mycobacterium tuberculosis

<400>  33
accatgagct tcaccgccca gcctgaaatg ctggccgctg ctgctggcga gctgagatct       60

ctgggagcca cactgaaggc cagcaatgcc gctgccgccg tgcctacaac aggcgtggtg      120

cctcctgccg ccgatgaagt gtctctgctg ctggccaccc agttcagaac ccacgccgcc      180

acataccaga ccgcctctgc caaagccgcc gtgatccacg agcagttcgt gaccacactg      240

gccaccagcg ccagctccta cgccgataca gaggccgcca atgccgtcgt gacaggctga      300

tttttct                                                                307


